Streamlining Infectious Disease GLP-1 Prior Auth Workflows

For Infectious Disease practices, managing the growing volume of GLP-1 prior authorizations presents a unique challenge. Klivira automates the infectious disease GLP-1 prior auth process, integrating with your EMR to reduce administrative burden.

Infectious Disease (ID) specialists frequently manage patients with complex comorbidities, including Type 2 Diabetes (T2D) and obesity, for whom GLP-1 receptor agonists are increasingly prescribed. The prior authorization requirements for these medications, particularly for obesity indications, add significant administrative overhead to clinics already navigating high-cost antivirals, antifungals, and OPAT therapies. Klivira's platform is designed to alleviate this burden.

The Unique Intersection of ID and GLP-1 Prior Authorization

ID patients, such as those with HIV or chronic viral hepatitis, often have metabolic complications requiring GLP-1 medications like Ozempic, Wegovy, Mounjaro, Zepbound, or Saxenda. While T2D indications are generally covered, obesity coverage varies widely by payer. This necessitates a robust system to differentiate indications, manage step therapy requirements, and ensure accurate documentation from often extensive ID patient records, impacting revenue cycle efficiency.

Common GLP-1 Prior Authorization Triggers in Infectious Disease

Prescription of high-cost GLP-1 receptor agonists (e.g., semaglutide, tirzepatide, liraglutide).
Payer-specific step therapy requirements for GLP-1s, often involving metformin trial history.
Documentation of BMI and relevant comorbidities for obesity indications.
A1C levels and T2D diagnosis for diabetes indications, per guidelines like ADA Standards of Care.
Varying payer coverage policies for anti-obesity medications vs. T2D treatments.

Klivira's Automated Workflow for ID GLP-1 Prior Auth

Klivira streamlines the GLP-1 prior authorization process within your Infectious Disease practice. Our platform integrates with your EMR to intelligently classify indications, route based on payer-specific obesity coverage, and automate the collection of necessary clinical data, reducing manual effort and accelerating approvals.

Key Automation Steps for GLP-1 PAs in ID

**Indication Classification:** Klivira identifies T2D vs. obesity indication directly from EMR diagnosis and clinical context.
**Per-Payer Obesity-Coverage Routing:** Our policy engine maintains current payer obesity benefit status and routes the ePA accordingly.
**Step Therapy Documentation Automation:** Pulls metformin trial history, BMI documentation, and comorbidity status from FHIR-enabled EMRs.
**Brand-Specific Routing:** Applies unique prior authorization criteria for different GLP-1 products (e.g., Ozempic, Mounjaro, Wegovy).
**Specialty Pharmacy Fulfillment:** Facilitates post-approval routing to specialty pharmacies for many GLP-1 products.
**Patient Financial Counseling Integration:** Surfaces manufacturer copay programs and alternative coverage paths when an obesity indication is denied.

Optimizing EMR and Payer Interactions for GLP-1s

Effective GLP-1 prior authorization relies on seamless data exchange. Klivira leverages SMART on FHIR capabilities to extract critical patient data—such as diagnosis codes, A1C, BMI, and medication history—from your EMR. We connect directly with payer portals and utilize X12 278 transactions to submit comprehensive ePA requests, ensuring all clinical requirements are met for both T2D and obesity indications.

Frequently asked questions

Why are GLP-1 PAs particularly relevant to Infectious Disease practices?

ID practices often manage patients with complex comorbidities like HIV or chronic hepatitis, who frequently develop Type 2 Diabetes and obesity. These conditions necessitate GLP-1 medications, introducing a new layer of prior authorization complexity to an already demanding clinical and administrative workflow.

How does Klivira handle the distinction between T2D and obesity indications for GLP-1s?

Klivira's system automatically classifies the indication (T2D or obesity) based on EMR diagnosis and clinical context. It then applies payer-specific logic, routing the prior authorization request according to the payer's coverage policies for each indication, ensuring the correct documentation is submitted.

What documentation is typically required for GLP-1 prior authorizations?

Common requirements include diagnosis codes for T2D or obesity, current BMI, A1C levels, history of relevant comorbidities, and documentation of prior trials of other medications (e.g., metformin) for step therapy. Klivira automates the extraction of this data from your EMR.

Does Klivira integrate with our EMR to pull GLP-1 related patient data?

Yes, Klivira integrates with leading EMR systems using SMART on FHIR standards. This allows our platform to securely access and utilize patient data, such as diagnosis, lab results, and medication history, directly from your EMR to populate prior authorization requests for GLP-1s.

How does Klivira manage step therapy requirements for GLP-1s?

Klivira's system is designed to identify and document step therapy requirements for GLP-1 medications. It pulls relevant medication trial history, such as metformin use, directly from the EMR to ensure compliance with payer protocols, minimizing delays and denials.